Published in

Frontiers Media, Frontiers in Endocrinology, (6)

DOI: 10.3389/fendo.2015.00063

Links

Tools

Export citation

Search in Google Scholar

IGF-I Influences Everolimus Activity in Medullary Thyroid Carcinoma

Journal article published in 2015 by Erica Gentilin, Carmelina Di Pasquale, Martina Rossi, Federico Tagliati, Teresa Gagliano ORCID, Roberta Rossi, Mariarosa Pelizzo, Isabella Merante Boschin, Isabella Merante Boschin, Ettore C. degli Uberti, Maria Chiara Zatelli ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Context: Medullary thyroid carcinoma (MTC) is a rare tumor originating from thyroid parafollicular C cells. It has been previously demonstrated that insulin-like growth factor I (IGF-I) protects MTC from the effects of antiproliferative drugs. Everolimus, an mTOR inhibitor, has shown potent antiproliferative effects in a human MTC cell line, TT, and in two human MTC primary cultures. Objective: To verify whether IGF-I may influence the effects of everolimus in a group of human MTC primary cultures. Design: We collected 18 MTCs that were dispersed in primary cultures, treated without or with 10 nM-1 mu M everolimus and/or 50 nM IGF-I. Cell viability was evaluated after 48 h, and calcitonin (CT) secretion was assessed after a 6 h incubation. IGF-I receptor downstream signaling protein expression profile was also investigated. Results: Everolimus significantly reduced cell viability in eight MTC [by similar to 20%; P